A Second View: Getting an endocrinologist's view on Rezvoglar and other available interchangeable biosimilar insulin products in managing diabetes

Executed on:Jan 5, 2023 1:30 PM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: University of TexasAssistant Professor of Endocrinology at Univeristy of Texas.
Treats 600 patients with Type-2 Diabetes.
Clinical interests include adrenal pathology, calcium disorders, endocrine neoplasia and resistant hypertension.

Interview Goal

This conversation will focus on the biosimilar insulin market landscape with a focus on Rezvoglar, Semglee, and Lantus. The FDA approved for Rezvoglar (insulin glargine-aglr), a biosimilar for Lantus (insulin glargine) that was originally approved in December 2021, for an interchangeability designation, allowing the product to be exchanged for the reference product at the pharmacy level without requiring physician permission.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.